Skip to main content

Published locations for FDA: Safety signal emerged with higher dose of tofacitinib in RA study

Primary tabs

View
Get Stamp Tags
Published Locations

Breadcrumb

Home
FDA: Safety signal emerged with higher dose of tofacitinib in RA study

User login

Username

Password

Reset your password

/content/fda-safety-signal-emerged-higher-dose-tofacitinib-ra-study
/clinicianreviews/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose
/edermatologynews/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose
/gihepnews/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose-tofacitinib-ra
/hematologynews/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose-tofacitinib
/internalmedicinenews/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose
/rheumatologynews/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose
/hematology-oncology/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose
/ecardiologynews/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose
/cardiology/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose-tofacitinib-ra
/rheumatology/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose-tofacitinib
/internalmedicine/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose
/dermatology/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose-tofacitinib-ra
/chestphysician/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose-tofacitinib
/rheumatology/psoriatic-arthritis-resource-center/article/195163/rheumatoid-arthritis/fda-safety
/dermatology/psoriasiscollection/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher
/psoriatic-arthritis-icymi/article/195163/rheumatoid-arthritis/fda-safety-signal-emerged-higher-dose